These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA Drugs; 2016 Jun; 76(9):925-45. PubMed ID: 27229745 [TBL] [Abstract][Full Text] [Related]
43. Neoadjuvant trials could speed up drug approvals. Peres J J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911 [No Abstract] [Full Text] [Related]
45. JAMA Oncology Patient Page. The Evolution of a Cancer. West HJ; Jin JO JAMA Oncol; 2015 Sep; 1(6):850. PubMed ID: 26247697 [No Abstract] [Full Text] [Related]
48. Introducing the BECT (biologically enhanced cytotoxic treatment) concept in cancer treatment. Bernier J; Bourhis J Ann Oncol; 2005 Nov; 16(11):1722. PubMed ID: 16087695 [No Abstract] [Full Text] [Related]
49. [Evolution of the parameters indicating response to drug therapy: from regression to complete control of the disease and the symptoms]. Cascinu S; Camisa R; D'Angelo A; Salvagni S Tumori; 2002; 88(6):A7-9. PubMed ID: 12597158 [No Abstract] [Full Text] [Related]
50. [Rationales for the integration of molecular and conventional therapies]. Tortora G; Ciardiello F Tumori; 2002; 88(6):A9-13. PubMed ID: 12597159 [No Abstract] [Full Text] [Related]
51. Clinical significance of epithelial-mesenchymal transition and cancer stem cells. Topcul M; Cetin I J BUON; 2016; 21(2):312-9. PubMed ID: 27273939 [TBL] [Abstract][Full Text] [Related]
52. Cancer stem cell targeted therapy: progress amid controversies. Wang T; Shigdar S; Gantier MP; Hou Y; Wang L; Li Y; Shamaileh HA; Yin W; Zhou SF; Zhao X; Duan W Oncotarget; 2015 Dec; 6(42):44191-206. PubMed ID: 26496035 [TBL] [Abstract][Full Text] [Related]
53. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers. Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305 [TBL] [Abstract][Full Text] [Related]
54. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. de Gramont A; Watson S; Ellis LM; Rodón J; Tabernero J; de Gramont A; Hamilton SR Nat Rev Clin Oncol; 2015 Apr; 12(4):197-212. PubMed ID: 25421275 [TBL] [Abstract][Full Text] [Related]